Publikasjoner

Recent and selected publications:

2010

Skogen Br, Killie MKr, Kjeldsen-Kragh J, Ahlen MT, Tiller H, Stuge TB, Husebekk A: Reconsidering fetal and neonatal alloimmune thrombocytopenia with a focus on screening and prevention. Expert Review of Hematology 3(5):559, 2010.

(open access: http://www.expert-reviews.com/doi/pdf/10.1586/ehm.10.49)

Killie MK, Salma W, Bertelsen E, Skogen B, Husebekk A: Quantitative MAIPA: Comparison of different MAIPA protocols. Transfus Apher Sci 43(2):149, 2010.

N. Baryawno, B. Sveinbjørnsson, P. Kogner, JI. Johnsen (2010). Medulloblastoma: A disease with disorganized developmental signaling cascades. Cell Cycle. (Published online ahead of print)

N. Baryawno, B. Sveinbjørnsson, S. Eksborg, C-S. Chen, P. Kogner. (2010).Small molecule inhibitors of phosphatidylinositol 3-kinase/Akt signalling inhibit Wnt/beta-catenin pathway crosstalk and suppress medulloblastoma growth. Cancer Res. 70:266-276.

2009

Skogen B, Husebekk A, Killie MK, Kjeldsen-Kragh J: Neonatal alloimmune thrombocytopenia is not what it was: a lesson learned from a large prospective screening and intervention program. Scand J Immunol 70(6):531, 2009.

Husebekk A, Killie MK, Kjeldsen-Kragh J, Skogen B: Is it time to implement HPA-1 screening in pregnancy? Curr Opin Hematol, 2009.

Tiller H, Killie MK, Skogen B, Oian P, Husebekk A: Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme. Bjog 116(4):594, 2009.

Ahlen MT, Husebekk A, Killie MK, Skogen B, Stuge TB: T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a-specific, HLA-DRB3*0101-restricted CD4+ T cells. Blood 113(16):3838, 2009.

Hanaka H, , Pawelzik, SC, Johnsen JI, Rakonjac M, Terawaki K, Rasmuson A, Sveinbjörnsson B, Schumacher, M.,Hamberg M ,Samuelsson B, Jakobson PJ, Kogner P, Rådmark O.(2009). Microsomal prostaglandin E synthase-1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci USA (PNAS) 106:18757-18762.

2008

Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B: A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 93(6):870, 2008.

B.Sveinbjörnsson, A. Rasmuson, N. Baryawno, M. Wan, I. Pettersen, F. Phontan,  A. Orrego, J. Haeggstrom, J.I. Johnsen and P. Kogner (2008). Leukotriene pathway in neuroblastomatumorigenesis and effect of leukotriene inhibition on neuroblastomatumor growth.  FASEB JOURNAL 22:3525-3536.

NinibBaryawno, Baldur Sveinbjörnsson, StaffanEksborg, AbielOrrego, LovaSegerström, Carl Otto Öqvist, Stefan Holm, BengtGustavsson, Per Kogner, John I. Johnsen (2008). Cyclooxygenase-2, prostaglandin E2 and prostanoid receptor expression promote medulloblastomatumor growth and provides new therapy targets .Neuro-Oncology.;10(5):661-74.

Johnsen, JI, Sgerstrom, L., Orrego, A. Elfman, L., Henriksson, M., Kågedal, B., Eksborg, S.,Sveinbjörnsson, B., Kogner, P. (2008).Inhibitors of mammalian target of rapamycindownregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene:  27:2910-2922.

2007

Kaplan C, Freedman J, Foxcroft Z, Husebekk A, Metcalfe P, Muniz-Diaz E, Ouwehand W, Panzer S, Rozman P, Skogen B: Monoclonal platelet antigen capture assays (MAIPA) and reagents: a statement. Vox Sang 93(4):298, 2007.

Kjeldsen-Kragh J, Killie MK, Tomter G, Golebiowska E, Randen I, Hauge R, Aune B, Oian P, Dahl LB, Pirhonen J, Lindeman R, Husby H, Haugen G, Gronn M, Skogen B, Husebekk A: A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 110(3):833, 2007.

Killie MK, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen JA, Kristiansen IS: Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. Bjog 114(5):588, 2007.

Killie MK, Husebekk A, Kaplan C, Taaning E, Skogen B: Maternal human platelet antigen-1a antibody level correlates with the platelet count in the newborns: a retrospective study. Transfusion 47(1):55, 2007.

Wickström, M., Johnsen, J.I.,Ponthan, F., Lindskog, M., Segerström,L., Sveinbjörnsson, B., Lövborg, H., Viktorsson, K., Lewensohn, R., Kogner, P., Larsson, R., Gullbo, J. (2007) The novel melphalan pro-drug J1 inhibits neuroblastoma growth in vitro and in vivo. Mol Cancer Ther.6:2409-17.

F. Ponthan, J.I.Johnsen, H.Gleisman, B. Sveinbjörnsson, P. Kogner (2007). Celecoxib prevents neuroblastomatumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin. Cancer Res. 13:1036-44.